1. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I
- Author
-
Robert Huddart, Johannes Classen, Roberto Salvioni, Rainer Souchon, Walter Albrecht, Xavier Garcia del Muro, Malcolm David Mason, Michael Bamberg, Johnathan Joffe, Jutta Scheiderbauer, Annette Dieing, Oscar Leiva Galvis, Niels E. Skakkebæk, Ronald de Wit, William G. Jones, Sophie D. Fosså, Kai Uwe Koehrmann, H. G. Derigs, Silke Gillessen, Martin Fenner, Sergei Tjulandin, C Clemm, Wolfgang Hoeltl, Padraig Warde, Aude Flechon, Luis Paz Ares, Pieter H.M. De Mulder, S. Kliesch, Nicola Nicolai, Thomas Powles, László Kisbenedek, Lothar Weissbach, Craig R. Nichols, Hans von der Maase, Michael Jewett, Jörg Pont, Markus A. Kuczyk, Volker Loy, Christian Wittekind, Peter Albers, Jose Ramon Germa-Lluch, Felix Sedlmayer, Giovanni Rosti, D. Ondruš, Pilar Laguna, Heinz Schmidberger, István Bodrogi, Gabriella Cohn-Cedermark, Eva Cavallin-Ståhl, Jörg Beyer, Tim Oliver, Arthur Gerl, Gedske Daugaard, Stefan Weinknecht, Tobias Pottek, Hans-Joachim Schmoll, Maike de Wit, Rolf Mueller, Maria De Santis, Michael Hartmann, Graham M. Mead, Oliver Rick, Jean Pierre Droz, Christian K. Kollmannsberger, Hans U. Schmelz, Karim Fizazi, Gosse O N Oosterhof, Lori Wood, Thomas Gauler, Aslam Sohaib, Susanne Krege, Ferran Algaba, Alan Horwich, Eva Winter, Stéphane Culine, Giorgio Pizzocaro, Olbjørn Klepp, Axel Heidenreich, Klaus Peter Dieckmann, Jörg T. Hartmann, Mark Schrader, Lajos Géczi, Carsten Bokemeyer, Department of Urology, Klinikum Kassel GmbH, Department of Molecular Genetics and Department of Chemotherapy, National Institute of Oncology, Endocrinologie moléculaire et cellulaire des cancers, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'oncologie Médicale, CRLCC Val d'Aurelle - Paul Lamarque, Dept of Oncology, Rigshospitalet [Copenhagen], Copenhagen University Hospital-Copenhagen University Hospital, Science et Ingénierie des Matériaux et Procédés (SIMaP), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National Polytechnique de Grenoble (INPG)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Génomes et cancer (GC (FRE2939)), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS), Departments of Clinical Cancer Research and genetics, Rikshospitalet-Radiumhospitalet Trust, Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de biologie moléculaire des plantes (IBMP), Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Dept of Urological Oncology, Phillips university, Academic Radiotherapy Unit, Institute of cancer research, Princess Margaret Hospital, University of Toronto, Department of Chemistry [Rochester], University of Rochester [USA], Department of Medical Oncology, Barts and The London Queen Mary's School of Medicine, Laboratoire Evolution, Génomes et Spéciation (LEGS), Centre National de la Recherche Scientifique (CNRS), Laboratory of Clinical Genetics, Institute of Clinical Oncology, Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), and Medical Oncology
- Subjects
Male ,MESH: Combined Modality Therapy ,Biopsy ,Consensus Development Conferences as Topic ,030232 urology & nephrology ,Membrane transport and intracellular motility [NCMLS 5] ,MESH: Biopsy ,0302 clinical medicine ,Stage I Seminoma ,MESH: Practice Guidelines as Topic ,Medicine ,Societies, Medical ,MESH: Testicular Neoplasms ,Consensus conference ,MESH: Neoplasm Staging ,Neoplasms, Germ Cell and Embryonal ,Prognosis ,Primary tumor ,Combined Modality Therapy ,3. Good health ,Europe ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,MESH: Neoplasms, Germ Cell and Embryonal ,medicine.medical_specialty ,[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT] ,Consensus ,Urology ,MESH: Societies, Medical ,MEDLINE ,MESH: Prognosis ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,Testicular Neoplasms ,Interventional oncology [UMCN 1.5] ,Humans ,MESH: Consensus ,Testicular cancer ,Neoplasm Staging ,Gynecology ,MESH: Humans ,business.industry ,MESH: Consensus Development Conferences as Topic ,medicine.disease ,MESH: Male ,Clinical trial ,Germ cell cancer ,Family medicine ,Germ cell tumors ,MESH: Europe ,business - Abstract
Objectives: The first consensus report presented by the European Germ Cell Cancer Consensus Group (EGCCCG) in the year 2004 has found widespread approval by many colleagues throughout the world. In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, Amsterdam, The Netherlands. Methods: Medical oncologists, urological surgeons, radiation oncologists as well as pathologists from several European countries reviewed and discussed the data that had emerged since the 2002 conference, and incorporated the new data into updated and revised guidelines. As for the first meeting, the methodology of evidence-based medicine (EBM) was applied. The results of the discussion were compiled by the writing committee. All participants have agreed to this final update. Results: The first part of the consensus paper describes the clinical presentation of the primary tumor, its treatment, the importance and treatment of testicular intraepithelial neoplasia (TIN), histological classification, staging and prognostic factors, and treatment of stage I seminoma and non-seminoma. Conclusions: Whereas the vast majority of the recommendations made in 2004 remain valid 3 yr later, refinements in the treatment of early- and advanced-stage testicular cancer have emerged from clinical trials. Despite technical improvements, expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer. In addition, the particular needs of testicular cancer survivors have been acknowledged. (C) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved.
- Published
- 2008